X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
Canada
0
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
1. 6 Dehydro 9 Beta 10 Alpha Progesterone
2. 6-dehydro-9 Beta-10 Alpha-progesterone
3. Dehydrogesterone
4. Duphaston
5. Isopregnenone
1. 152-62-5
2. Isopregnenone
3. Hydrogesterone
4. Duphaston
5. Hydrogestrone
6. Gynorest
7. Gestatron
8. Diphaston
9. Dufaston
10. 10alpha-isopregnenone
11. Duvaron
12. Prodel
13. Retrone
14. Terolut
15. Retro-6-dehydroprogesterone
16. Didrogesterone [dcit]
17. Didrogesterone
18. Dydrogesteronum
19. Delta(6)-retroprogesterone
20. 6-dehydro-retro-progesterone
21. Dydrogesteronum [inn-latin]
22. Dydrogesterona [inn-spanish]
23. Delta(sup 6)-retroprogesterone
24. 9beta,10alpha-pregna-4,6-diene-3,20-dione
25. Retroprogesterone, 6-dehydro-
26. (8s,9r,10s,13s,14s,17s)-17-acetyl-10,13-dimethyl-1,2,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one
27. Nsc-92336
28. (9beta,10alpha)-pregna-4,6-diene-3,20-dione
29. Mls002153947
30. 90i02kle8k
31. Chebi:31527
32. Dydrogesterona
33. Dsstox_cid_2974
34. Dsstox_rid_76812
35. Dsstox_gsid_22974
36. Didrogesterona
37. Duphaston (tn)
38. Gynorest (tn)
39. 6-dehydro-9beta,10alpha-progesterone
40. Cas-152-62-5
41. Ccris 9069
42. Hsdb 3321
43. Mls002695106
44. 6-dehydroretroprogesterone
45. Einecs 205-806-8
46. 9-beta,10alpha-pregna-4,6-diene-3,20-dione
47. Nsc 92336
48. (9-beta,10-alpha)-pregna-4,6-diene-3,20-dione
49. Pregna-4,6-diene-3,20-dione, (9beta,10alpha)-
50. Unii-90i02kle8k
51. Nsc92336
52. 9-beta,10-alpha-pregna-4,6-diene-3,20-dione
53. Ncgc00016413-01
54. Dydrogesterone [usan:usp:inn:ban:jan]
55. 6-dehydro-9.beta.,10.alpha.-progesterone
56. Prestwick0_000671
57. Prestwick1_000671
58. Prestwick2_000671
59. Prestwick3_000671
60. Dydrogesterone [mi]
61. Pregna-4,6-diene-3,20-dione, (9b,10a)-
62. .delta.6-retroprogesterone
63. Dydrogesterone [inn]
64. Dydrogesterone [jan]
65. Schembl37703
66. Bspbio_000761
67. Dydrogesterone [hsdb]
68. Dydrogesterone [usan]
69. 9.beta.,10.alpha.-pregna-4,6-diene-3,20-dione
70. Spbio_002682
71. Dydrogesterone [mart.]
72. Bpbio1_000839
73. Gtpl2878
74. Pregna-4,6-diene-3,20-dione, (9-beta,10-alpha)-
75. Dydrogesterone [usp-rs]
76. Dydrogesterone [who-dd]
77. Chembl1200853
78. Dtxsid1022974
79. Hy-b0257a
80. 9.beta.,6-diene-3,20-dione
81. Dydrogesterone (jp17/usp/inn)
82. Hms1570g03
83. Hms2097g03
84. Hms2230c10
85. Hms3714g03
86. 9-.beta.,6-diene-3,20-dione
87. Amy23414
88. Bcp12878
89. Zinc3875998
90. Dydrogesterone [orange Book]
91. Tox21_110429
92. Dydrogesterone [ep Monograph]
93. S4097
94. Dydrogesterone [usp Monograph]
95. Akos015895532
96. Tox21_110429_1
97. Ccg-220671
98. Db00378
99. Gs-6735
100. Ncgc00179445-01
101. Ncgc00179445-03
102. Ncgc00179445-04
103. Smr001233286
104. Ab00513884
105. (9?,10?)-pregna-4,6-diene-3,20-dione
106. D01217
107. H10151
108. Pregna-4,20-dione, (9.beta.,10.alpha.)-
109. Ab00513884_04
110. 152d625
111. Sr-01000841256
112. Q4161380
113. Sr-01000841256-2
114. W-108050
115. Brd-k68620903-001-03-1
116. Brd-k68620903-001-11-4
117. Pregna-4,6-diene-3,20-dione, (9.beta.,10.alpha.)
118. (1r,2s,10s,11s,14s,15s)-14-acetyl-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-6,8-dien-5-one
119. (8s,9r,10s,13s,14s,17s)-17-acetyl-10,13-dimethyl-8,9,10,11,12,13,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3(2h)-one
| Molecular Weight | 312.4 g/mol |
|---|---|
| Molecular Formula | C21H28O2 |
| XLogP3 | 3.8 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 1 |
| Exact Mass | 312.208930132 g/mol |
| Monoisotopic Mass | 312.208930132 g/mol |
| Topological Polar Surface Area | 34.1 Ų |
| Heavy Atom Count | 23 |
| Formal Charge | 0 |
| Complexity | 628 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 6 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Progestational Hormones, Synthetic
National Library of Medicine's Medical Subject Headings online file (MeSH, 2009)
/Dydrogesterone is indicated as/ Hormone replacement therapy (HRT) for estrogen deficiency symptoms in peri and postmenopausal women. Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis.
Datapharm Communications Ltd; Electronic Medicines Compendium (eMC), Summary of Product Characteristics (SPC) for Femoston (Last updated February 2011). Available from, as of March 2, 2011: https://www.medicines.org.uk/EMC/medicine/2493/SPC/Femoston+1+10mg/
/EXPTL THER:/ The aim of the present study was to evaluate dydrogesterone for luteal-phase support in assisted reproductive technologies (ART) and to compare it with micronized vaginal progesterone. All patients underwent long-term downregulation with gonadotropin-releasing hormone agonists. In phase I, 498 patients were divided into three groups: long protocol and not at risk of ovarian hyperstimulation syndrome (OHSS) (group A); long protocol and at risk of OHSS (group B); and those in a donor oocyte program (group C). All patients received micronized progesterone 600 mg/day, vaginally. They were also randomized to dydrogesterone 20 mg/day (n = 218) or placebo (n = 280). The pregnancy rate was higher with dydrogesterone than with placebo in group A (33.0% vs. 23.6%), group B (36.8% vs. 28.1%) and group C (42.9% vs. 15.6%; p < 0.001). In phase II, 675 patients were divided into the same three groups (groups D, E and F) and were randomized to dydrogesterone 30 mg/day (n = 366) or micronized progesterone 600 mg/day (n = 309). The pregnancy rate was significantly higher with dydrogesterone than with progesterone in group D (39.1% vs. 26.7%; p < 0.01), group E (41.2% vs. 35.6%; p < 0.01) and group F (48.2% vs. 33.9%; p < 0.001). In conclusion, dydrogesterone is effective in luteal-phase support in ART.
PMID:17943542 Patki A, Pawar VC; Gynecol Endocrinol 23 Suppl 1: 68-72 (2007)
Dydrogesterone has no inherent estrogenic activity and no androgenic effects. Priming with estrogen is necessary prior to use. Drug is claimed to be nonthermogenic and does not consistently inhibit ovulation.
American Medical Association, AMA Department of Drugs, AMA Drug Evaluations. 3rd ed. Littleton, Massachusetts: PSG Publishing Co., Inc., 1977., p. 568
Spectrum of progestin therapy has changed & expanded during last few yr. Drug-therapy of choice in endometriosis is medication of progestins for at least 6 months. If patient wants additional children the "more gentle" dydrogesterone should be considered.
VOLKER W; FORTSCHR MED 95(2) 68 (1977)
There is no conclusive evidence for improvement of cognitive function. There is some evidence from the WHI trial of increased risk of probable dementia in women who start using continuous combined CEE and MPA after the age of 65. It is unknown whether the findings apply to younger post-menopausal women or other HRT products.
Datapharm Communications Ltd; Electronic Medicines Compendium (eMC), Summary of Product Characteristics (SPC) for Femoston (Last updated February 2011). Available from, as of March 2, 2011: https://www.medicines.org.uk/EMC/medicine/2493/SPC/Femoston+1+10mg/
For the treatment of postmenopausal symptoms, HRT should only be initiated for symptoms that adversely affect quality of life. In all cases, a careful appraisal of the risks and benefits should be undertaken at least annually and HRT should only be continued as long as the benefit outweighs the risk.
Datapharm Communications Ltd; Electronic Medicines Compendium (eMC), Summary of Product Characteristics (SPC) for Femoston (Last updated February 2011). Available from, as of March 2, 2011: https://www.medicines.org.uk/EMC/medicine/2493/SPC/Femoston+1+10mg/
Known, past or suspected breast cancer; Known or suspected estrogen-dependent malignant tumours (eg endometrial cancer); Undiagnosed genital bleeding; Untreated endometrial hyperplasia; Previous idiopathic or current venous thromboembolism (deep vein thrombosis, pulmonary embolism); Active or recent arterial thromboembolic disease (eg angina, myocardial infarction); Acute liver disease or a history of liver disease as long as liver function tests have failed to return to normal; Known hypersensitivity to the active substances or to any of the excipients; Porphyria.
Datapharm Communications Ltd; Electronic Medicines Compendium (eMC), Summary of Product Characteristics (SPC) for Femoston (Last updated February 2011). Available from, as of March 2, 2011: https://www.medicines.org.uk/EMC/medicine/2493/SPC/Femoston+1+10mg/
Femoston is not indicated during pregnancy. If pregnancy occurs during medication with Femoston, treatment should be withdrawn immediately.
Datapharm Communications Ltd; Electronic Medicines Compendium (eMC), Summary of Product Characteristics (SPC) for Femoston (Last updated February 2011). Available from, as of March 2, 2011: https://www.medicines.org.uk/EMC/medicine/2493/SPC/Femoston+1+10mg/
For more Drug Warnings (Complete) data for DYDROGESTERONE (26 total), please visit the HSDB record page.
Used to treat irregular duration of cycles and irregular occurrence and duration of periods caused by progesterone deficiency. Also used to prevent natural abortion in patients who have a history of habitual abortions.
Dydrogesterone is an orally active progestogen which acts directly on the uterus, producing a complete secretory endometrium in an estrogen-primed uterus. At therapeutic levels, dydrogesterone has no contraceptive effect as it does not inhibit or interfere with ovulation or the corpus luteum. Furthermore, dydrogesterone is non-androgenic, non-estrogenic, non-corticoid, non-anabolic and is not excreted as pregnanediol. Dydrogesterone helps to regulate the healthy growth and normal shedding of the uterus lining. Therefore, it may be useful in the treatment of menstrual disorders such as absent, irregular or painful menstrual periods, infertility, premenstrual syndrome and endometriosis.
Progestins
Compounds that interact with PROGESTERONE RECEPTORS in target tissues to bring about the effects similar to those of PROGESTERONE. Primary actions of progestins, including natural and synthetic steroids, are on the UTERUS and the MAMMARY GLAND in preparation for and in maintenance of PREGNANCY. (See all compounds classified as Progestins.)
G03DB01
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
G - Genito urinary system and sex hormones
G03 - Sex hormones and modulators of the genital system
G03D - Progestogens
G03DB - Pregnadien derivatives
G03DB01 - Dydrogesterone
Absorption
Rapidly absorbed in the gastrointestinal tract with a bioavailability of 28%.
After oral administration of labelled dydrogesterone, on average 63% of the dose is excreted into the urine. Within 72 hours, excretion is complete.
Datapharm Communications Ltd; Electronic Medicines Compendium (eMC), Summary of Product Characteristics (SPC) for Femoston (Last updated February 2011). Available from, as of March 2, 2011: https://www.medicines.org.uk/EMC/medicine/2493/SPC/Femoston+1+10mg/
After oral administration of dydrogesterone, plasma concentrations of DHD are substantially higher as compared to the parent drug. The AUC and Cmax ratios of DHD to dydrogesterone are in the order of 40 and 25, respectively. Dydrogesterone is rapidly absorbed. The Tmax values of dydrogesterone and DHD vary between 0.5 and 2.5 hours.
Datapharm Communications Ltd; Electronic Medicines Compendium (eMC), Summary of Product Characteristics (SPC) for Femoston (Last updated February 2011). Available from, as of March 2, 2011: https://www.medicines.org.uk/EMC/medicine/2493/SPC/Femoston+1+10mg/
The dihydrodydrogesterone Caverage is 13 ng/mL, the Cmin is 4.1 ng/mL and the Cmax is 63 ng/mL. The dydrogesterone Caverage is 0.38 ng/mL the Cmin is <0.1 ng/mL and the Cmax is 2.5 ng/mL.
Datapharm Communications Ltd; Electronic Medicines Compendium (eMC), Summary of Product Characteristics (SPC) for Femoston (Last updated February 2011). Available from, as of March 2, 2011: https://www.medicines.org.uk/EMC/medicine/2493/SPC/Femoston+1+10mg/
Progestins are reportedly distributed into milk. The possible effects of progestins in milk on nursing infants have not been determined. /Progestins General Statement/
American Society of Health System Pharmacists; AHFS Drug Information 2010. Bethesda, MD. (2010), p. 3270
Metabolism is complete to a 20-dihydrodydrogesterone (DHD) metabolite.
In man, dydrogesterone is completely metabolised. The main metabolite of dydrogesterone is 20alpha-dihydrodydrogesterone (DHD) and is present in the urine predominantly as the glucuronic acid conjugate. A common feature of all metabolites characterized is the retention of the 4,6 diene-3-one configuration of the parent compound and the absence of 17alpha-hydroxylation. This explains the absence of estrogenic and androgenic activity.
Datapharm Communications Ltd; Electronic Medicines Compendium (eMC), Summary of Product Characteristics (SPC) for Femoston (Last updated February 2011). Available from, as of March 2, 2011 : https://www.medicines.org.uk/EMC/medicine/2493/SPC/Femoston+1+10mg/
Dydrogesterone is not excreted in urine as pregnanediol, like progesterone. Analysis of endogenous progesterone production based on pregnanediol excretion therefore remains possible.
Datapharm Communications Ltd; Electronic Medicines Compendium (eMC), Summary of Product Characteristics (SPC) for Femoston (Last updated February 2011). Available from, as of March 2, 2011:: https://www.medicines.org.uk/EMC/medicine/2493/SPC/Femoston+1+10mg/
Dydrogesterone: 5-7 hours, 20-dihydrodydrogesterone (DHD) metabolite: 14-17 hours
Mean terminal half lives of dydrogesterone and DHD vary between 5 to 7 and 14 to 17 hours, respectively.
Datapharm Communications Ltd; Electronic Medicines Compendium (eMC), Summary of Product Characteristics (SPC) for Femoston (Last updated February 2011). Available from, as of March 2, 2011: https://www.medicines.org.uk/EMC/medicine/2493/SPC/Femoston+1+10mg/
Dydrogesterone is a progestogen that works by regulating the healthy growth and normal shedding of the womb lining by acting on progesterone receptors in the uterus.
Dydrogesterone is an orally-active progestagen. The addition of a progestagen greatly reduces the estrogen-induced risk of endometrial hyperplasia and cancer in non-hysterectomised women, by reducing the growth of the endometrium.
Datapharm Communications Ltd; Electronic Medicines Compendium (eMC), Summary of Product Characteristics (SPC) for Femoston (Last updated February 2011). Available from, as of March 2, 2011: https://www.medicines.org.uk/EMC/medicine/2493/SPC/Femoston+1+10mg/
Progestins cannot be equated as group with progesterone because some are inherently estrogenic, some slightly androgenic, and some purely progestational; correspondingly, their ovulation-inhibiting potentialities may be mediated in somewhat different ways. /Progestins/
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1444
The 17-hydroxy or acetoxy compounds, on the other hand, elicit responses more nearly resembling those of progesterone. They have little or no estrogenic or androgenic activity and may produce catabolic and slight diuretic effects. The 19-nor derivatives are more effective in postponing the normal menstrual period. /Progestins/
American Society of Health System Pharmacists; AHFS Drug Information 2010. Bethesda, MD. (2010), p. 3271
Accumulating evidence indicates that the neuropeptide substance P (SP) is predominantly involved in neurogenic inflammation and pain perception via its high-affinity neurokinin 1 receptor (NK-1R). Intriguingly, decreased pain sensitivity is found to be associated with high plasma progesterone levels. We hypothesize that progesterone may attenuate nociception and associated inflammatory response via NK-1R-dependent pathways. To address our hypothesis, we incubated splenic lymphocytes from CBA/J female mice with different concentrations of the progesterone derivative dydrogesterone. Subsequently, the expressions of NK-1R and T helper (Th1)-type cytokines were analyzed by flow cytometry. Next, we subcutaneously injected CBA/J mice with 1.25 mg of dydrogesterone in 200-microl sesame oil; control mice were sham-injected. Tail flick test to detect the nociceptive threshold was performed in 30-min intervals upon injection. Lymphocytes were isolated from blood and uterus and analyzed for NK-1R surface expression. Immunohistochemical analyses were performed to investigate the uterine tissue distribution of NK-1R. Dydrogesterone induced a decrease in the percentage of NK-1R+ lymphocytes in vitro and in vivo. Additionally, an increase in Th2-type and a decrease in Th1-type cytokines could be detected in vitro after incubation with dydrogesterone. An increased tail flick latency following dydrogesterone injection supported the concept that decreased expression of the NK-1R on lymphocytes is associated with an increased pain threshold. Taken together, these results clearly reveal a pathway by which dydrogesterone or progesterone respectively modulates the cross talk of the nervous, endocrine and immune systems in inflammation and pain.
PMID:16389545 Orsal AS et al; J Mol Med 84 (2): 159-67 (2006)
For more Mechanism of Action (Complete) data for DYDROGESTERONE (6 total), please visit the HSDB record page.
Market Place
